Crinetics Pharmaceuticals (NASDAQ:CRNX) and Cogent Biosciences (NASDAQ:COGT) Head to Head Analysis

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Crinetics Pharmaceuticals and Cogent Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	0	1	10	0	2.91
Cogent Biosciences	0	2	5	0	2.71

Crinetics Pharmaceuticals presently has a consensus price target of $68.55, indicating a potential upside of 28.97%. Cogent Biosciences has a consensus price target of $14.67, indicating a potential upside of 33.58%. Given Cogent Biosciences’ higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Crinetics Pharmaceuticals.

Profitability

This table compares Crinetics Pharmaceuticals and Cogent Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	N/A	-37.03%	-32.41%
Cogent Biosciences	N/A	-100.92%	-57.67%

Institutional and Insider Ownership

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Crinetics Pharmaceuticals and Cogent Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$1.39 million	3,026.29	-$214.53 million	($3.78)	-14.06
Cogent Biosciences	N/A	N/A	-$192.41 million	($2.48)	-4.43

Cogent Biosciences has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Crinetics Pharmaceuticals has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.

Summary

Crinetics Pharmaceuticals beats Cogent Biosciences on 7 of the 12 factors compared between the two stocks.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About Cogent Biosciences

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.